Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1801)	11/16/2007 1:25:42 AM
From: Icebrg	Read Replies (2) \| Respond to of 1826

MGI Pharma "neutral" Monday, November 12, 2007 10:42:32 AM ET Robert W. Baird NEW YORK, November 12 (newratings.com) - Analyst Christopher J Raymond of Robert W Baird reiterates his "neutral" rating on MGI Pharma Inc (MOGN.NAS). The target price is set to $30. In a research note published this morning, the analyst mentions that the data on two Phase II Dacogen trials would be released at ASH. Vidaza's Survival Study has indicated a survival benefit in patients suffering from high-risk MDS, the analyst says. Although Dacogen's commercial progress so far has been quite good, there is concern that the momentum might shift towards Vidaza, Robert W Baird adds.